THRA

Across TCGA pan-cancer cohorts, THRA RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of THRA’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where THRA RNA is repressed in tumor relative to normal tissue. In most cancer types THRA is over-expressed in tumor, although a few such as BLCA and LUAD show the opposite, repressed pattern.

BLCA, LIHC, and LUAD are the cancer types where THRA tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in THRA RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	III,IV	−2.297	<.001	10	view →
LIHC	Female	II,III,IV	+1.648	<.001	9	view →
LUAD	Female	All	−1.154	<.001	9	view →
THCA	Male	III,IV	−0.704	<.001	9	view →
KICH	Male	All	−1.165	<.001	8	view →
UCEC	All	All	−1.871	<.001	6	view →
BRCA	Female	II,III,IV	−1.178	<.001	6	view →
LUSC	Male	II,III,IV	−1.089	<.001	6	view →
KIRC	All	II,III,IV	−0.435	.002	4	view →
CHOL	All	All	+2.521	<.001	3	view →
READ	All	II,III,IV	−0.745	.007	3	view →
PRAD	All	All	−0.428	<.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

THRA–BLCA

Open the BLCA breakdown →